In this regard, imaging with the next-generation tau-PET tracer [18F]PI-2620 facilitated discrimination of patients with a clinical diagnosis of the 4RTs progressive supranuclear palsy (PSP) [1] and corticobasal syndrome (CBS) [2] from healthy controls, non-tauopathy Parkinson syndromes and Alzheimer’s disease (AD). This evidence concerns the gene MAPT and progressive supranuclear palsy.